This was the stock's third consecutive day of losses.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

On Friday, Abbott Laboratories (ABT) stock saw a decline, ending the day at $118.93 which represents a decrease of $-0.02 or -0.02% from the prior close of $118.95. The stock opened at $118.71 and ...

Piper Sandler analyst Adam Maeder maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...

Valued at a market cap of $202.6 billion, North Chicago, Illinois-based Abbott Laboratories (ABT) is a global healthcare ...

Abbott Laboratories (NYSE:ABT – Get Free Report) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 12,050,000 shares, a ...

The projected fair value for Abbott Laboratories is US$137 based on 2 Stage Free Cash Flow to Equity Abbott Laboratories' US$119 share price indicates it is trading at similar levels as its fair ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $116.41 ...

ABBOTT PRISM was specifically designed to automatically ... is now being used in most major hospitals and reference laboratories and is now available in the transfusion market.

Analysts see big upside for these undervalued health care stocks.

Copyright © 2024 MarketWatch, Inc. All rights reserved.